MicroRNA 345 (miR-345) (miR-345)

MicroRNA 345 (miR-345) is a small non-coding RNA molecule that serves as a key post-transcriptional regulator of gene expression, primarily acting as a tumor suppressor in various human cancers (NIH, 2019; MDPI, 2021). It is frequently downregulated in malignancies such as pancreatic, colorectal, lung, and breast cancers, often due to promoter hypermethylation (NIH, 2011; PLOS One, 2014). miR-345 exerts its biological effects by binding to the 3' untranslated regions (UTRs) of target mRNAs—including YAP1, ZEB2, BCL2, and ABCC1—leading to their degradation or translational inhibition, which in turn suppresses cell proliferation, migration, and invasion while promoting apoptosis (NIH, 2019; British Journal of Cancer, 2015). Beyond its role in oncology, miR-345 has been implicated in the pathogenesis of multiple sclerosis and polycystic liver disease, where it modulates inflammatory and proliferative pathways (Frontiers in Immunology, 2021; NIH, 2019). In the therapeutic landscape, miR-345 mimics are being explored to restore its tumor-suppressive function, often in combination with conventional chemotherapies like gemcitabine to overcome drug resistance (Journal of Controlled Release, 2018). Furthermore, its levels in circulating fluids like serum and saliva are being investigated as non-invasive biomarkers for disease diagnosis, prognosis, and the prediction of treatment response to agents such as cetuximab (MDPI, 2021; PLOS One, 2014).

Other names

MIR345hsa-mir-345MIRN345microRNA 345-5p

Restoration of tumor-suppressive function through the introduction of synthetic microRNA mimics that silence oncogenic target mRNAs via the RNA-induced silencing complex (RISC).